Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 240

Sort by

Sort Order Select

Journal Articles

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

Joseph M. Rocco, Joseph H. Oved, Rikita J Patel, A Zara Herskovits, Namitha Nair, Bita Shakoory, Thomas Robertson, Rachel Dileo, Max W Jacobs, Christa Zerbe, Rachael Gordon, Michael Joseph Ombrello, Amanda K Ombrello, Nirali N Shah, Dimana Dimitrova, Jennifer A Kanakry, Andrew D. Zelenetz, Alison J Moskowitz, Robert N Stuver, Zachary D Epstein-Peterson, Paola Ghione, Elena Mead, Zainab Shahid, Sergio A. Giralt, Sandeep S Raj, Jae H Park, Ivan Maillard, Mark B. Geyer, Wenbin Xiao, Ahmet Dogan, Megan S Lim, Jeffrey I. Zwicker, Jodi V. Mones, Rehka Parameswaran, Lauren G Banaszak, Shamir Geller, Bianca D. Santomasso, Roni Shouval, Kevin J. Curran, Ottavia M Delmonte, Luigi D Notarangelo, Jeffrey I Cohen, Steven M. Holland, Gilles A. Salles, Steven M Horwitz, Santosha A Vardhana, Miguel-Angel Perales, Daniella Schwartz, Irini Sereti, William T. Johnson

Blood blood.2025030976.

https://doi.org/10.1182/blood.2025030976

Published: 2025

Includes: Supplemental data

Journal Articles

AI-based diagnosis of cutaneous lymphoma and lymphoproliferative disorders via H&E morphology and LLM-assisted cohort curation

Ali Kamali, Khawaja Bilal, Zhanghan Yin, Argho Sarkar, Andrea Moy, Orly Ardon, Ahmet Dogan, Chad Vanderbilt, Melissa Pulitzer, Gregory Goldgof

Blood (2025) 146 (Supplement 1): 2564.

https://doi.org/10.1182/blood-2025-2564

Published: 2025

Journal Articles

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2025-1850

Published: 2025

Journal Articles

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 888.

https://doi.org/10.1182/blood-2025-888

Published: 2025

Journal Articles

Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL

Blood (2025) 146 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2025-1008

Published: 2025

Journal Articles

MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation

Blood (2025) 146 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2025-1766

Published: 2025

Journal Articles

Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis

Zachary Epstein-Peterson, Nivetha Ganesan, Ellie Casper, Tiffany Chang, Ahmet Dogan, Ozgur Can Eren, Natasha Galasso, Paola Ghione, Kelly Hannigan, Varun Iyengar, William Johnson, Jason Krastein, Katie Ksanznak, Alison Moskowitz, Brittney Munayiri, Benedetta Sordi, Robert Stuver, Jasmine Zain, Steven Horwitz

Blood (2025) 146 (Supplement 1): 5412.

https://doi.org/10.1182/blood-2025-5412

Published: 2025

Journal Articles

Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P

Blood (2025) 146 (Supplement 1): 5410.

https://doi.org/10.1182/blood-2025-5410

Published: 2025

Journal Articles

Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma

Mika Geva, Michelle Okwali, Lorenzo Falchi, Ahmet Dogan, Shenon Sethi, Alexander Boardman, Paul Hamlin, Paola Ghione, Colette Owens, Gilles Salles, Lia Palomba, Zachary Epstein-Peterson

Blood (2025) 146 (Supplement 1): 5374.

https://doi.org/10.1182/blood-2025-5374

Published: 2025

Journal Articles

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Blood (2025) 146 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2025-2756

Published: 2025

Journal Articles

Spen loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and TLR pathway therapeutic vulnerabilities

Blood (2025) 146 (Supplement 1): 140.

https://doi.org/10.1182/blood-2025-140

Published: 2025

Journal Articles

Image-based classification of lymphocyte subsets from routine blood smears reveals distinct immune dynamics after CAR-T infusion

Sean Paulsen, Greg Goldgof, Chad Vanderbilt, Cesar Colorado-Jimenez, Dylan Webb, Sapir Israeli, Anthony Cardillo, Ali Kamali, Maly Fenelus, Samuel McCash, Teng Fei, Linlin Wang, Lauren McVoy, Kai Rejeski, Roni Shouval, Ahmet Dogan

Blood (2025) 146 (Supplement 1): 4354.

https://doi.org/10.1182/blood-2025-4354

Published: 2025

Journal Articles

Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD

Blood (2025) 146 (Supplement 1): 3569.

https://doi.org/10.1182/blood-2025-3569

Published: 2025

Journal Articles

Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial

Blood (2025) 146 (Supplement 1): 463.

https://doi.org/10.1182/blood-2025-463

Published: 2025

Journal Articles

Anti-CD94 monoclonal antibody DR-01 induced response in a refractory primary CNS T-cell lymphoma

Christian Grommes, Alicia Assini, Marcel Smith, Angela Gibaldi, Autumn Mcdonnell, Ozgur Can Eren, Ting Zhou, Ahmet Dogan, Lauren Schaff, Steven Horwitz

Blood (2025) 146 (Supplement 1): 7172.

https://doi.org/10.1182/blood-2025-7172

Published: 2025

Journal Articles

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

Blood (2025) 146 (Supplement 1): 3605.

https://doi.org/10.1182/blood-2025-3605

Published: 2025

Journal Articles

Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype

Blood (2025) 145 (18): 2056–2069.

https://doi.org/10.1182/blood.2024026273

Published: 2025

Includes: Supplemental data

Journal Articles

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Blood (2025) 145 (5): 497–507.

https://doi.org/10.1182/blood.2024025563

Published: 2025

Includes: Supplemental data

Journal Articles

Adult AML Patients with NUP98 Fusions Are Frequently Therapy-Related, and Are Associated with Monocytic Differentiation, Recurring Mutations in NRAS , DNMT3A and WT1 and Poor Outcome

Jinjuan Yao, Umut Aypar, Shenon Sethi, Leora Boussi, Dory Londono, Purvil Sukhadia, Ellin Berman, Eytan M. Stein, Ahmet Dogan, Wenbin Xiao, Yanming Zhang

Blood (2024) 144 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2024-203634

Published: 2024

Journal Articles

Peripheral Blood Smear-Based Deep Learning to Predict Cancer-Associated Thrombosis

Deepika Dilip, Siddharth Singi, Dylan C. Webb, Cesar Colorado-Jimenez, Rohan Singh, Zhanghan Yin, Sean Paulsen, Lauren McVoy, Maly Fenelus, Mikhail Roshal, Chad Vanderbilt, Jeffrey I. Zwicker, Ahmet Dogan, Gregory Mark Goldgof, Simon Mantha

Blood (2024) 144 (Supplement 1): 2626.

https://doi.org/10.1182/blood-2024-202054

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

AI-based diagnosis of cutaneous lymphoma and lymphoproliferative disorders via H&E morphology and LLM-assisted cohort curation

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL

MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation

Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis

Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P

Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Spen loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and TLR pathway therapeutic vulnerabilities

Image-based classification of lymphocyte subsets from routine blood smears reveals distinct immune dynamics after CAR-T infusion

Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD

Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial

Anti-CD94 monoclonal antibody DR-01 induced response in a refractory primary CNS T-cell lymphoma

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Adult AML Patients with NUP98 Fusions Are Frequently Therapy-Related, and Are Associated with Monocytic Differentiation, Recurring Mutations in NRAS , DNMT3A and WT1 and Poor Outcome

Peripheral Blood Smear-Based Deep Learning to Predict Cancer-Associated Thrombosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only